Comparative Pharmacology
Head-to-head clinical analysis: RANICLOR versus ZANTAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RANICLOR versus ZANTAC.
RANICLOR vs ZANTAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ranitidine is a histamine H2-receptor antagonist that competitively inhibits the action of histamine on parietal cells, thereby reducing gastric acid secretion.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
12.5 mg orally twice daily, increased to 25 mg twice daily after 2 weeks if tolerated; maximum 50 mg twice daily.
150 mg orally twice daily or 50 mg intravenously every 6-8 hours. Alternatively, 300 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (mean 10 hours) in healthy adults; prolonged in renal impairment (up to 20 hours) and elderly.
2.5-3 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 20 hours in severe renal impairment (CrCl < 30 mL/min).
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Renal: 30% unchanged (tubular secretion); hepatic metabolism to N-oxide, S-oxide, and desmethyl ranitidine; biliary/fecal: minimal.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist